Clinical Trial Update: Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating an RSV and human metapneumovirus vaccine candidate sponsored by Sanofi Pasteur.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV/HMPV vaccine candidate

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers | Phase 1, Phase 2 | Status: COMPLETED